Jan. 5 at 6:30 PM
$ACFN Pancreatic program brought real heat in 2025, License and Option Agreement signed March 2025 with Liquid Biosciences to access novel mRNA biomarkers for a non-invasive blood-based pancreatic screening test with development aimed toward potential future FDA applications, that’s platform expansion with intent, company name in bio 🧬🔥